STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRNX
  4. [8-K] Crinetics Pharmaceuticals, Inc. Reports Material Event

Crinetics (NASDAQ: CRNX) investors approve directors, auditor and say-on-pay

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held via live webcast on June 18, 2026. Holders of 102,030,415 shares of common stock were present virtually or by proxy, representing approximately 97% of the outstanding shares eligible to vote.

Stockholders elected three Class II directors—Caren Deardorf, Weston Nichols, Ph.D., and Stephanie S. Okey, M.S.—to three-year terms expiring at the 2029 annual meeting. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares represented 102,030,415 shares Present virtually or by proxy at the June 18, 2026 annual meeting
Participation rate 97% Approximate percentage of outstanding shares eligible to be voted at the meeting
Auditor ratification votes for 101,675,974 votes Votes for ratifying PricewaterhouseCoopers LLP for fiscal year ending December 31, 2026
Auditor ratification votes against 341,727 votes Votes against ratifying PricewaterhouseCoopers LLP
Say-on-pay votes for 91,657,992 votes Votes for approving named executive officer compensation on an advisory basis
Say-on-pay votes against 2,698,538 votes Votes against approving named executive officer compensation
Broker non-votes 5,044,011 votes Broker non-votes recorded on the say-on-pay proposal
broker non-votes financial
"Votes For | Votes Against | Abstentions | Broker Non-Votes 91,657,992 | 2,698,538 | 2,629,874 | 5,044,011"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory basis financial
"approved, on an advisory basis, the compensation of the Company’s named executive officers"
emerging growth company regulatory
"Emerging growth company o o Item 5.07 Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001658247false00016582472026-06-182026-06-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________
FORM 8-K
_________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 18, 2026
_________________________________________________________
Crinetics Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
_________________________________________________________
Delaware001-3858326-3744114
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
6055 Lusk Boulevard
San Diego, California
92121
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (858) 450-6464
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per shareCRNXNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. (the “Company”) was held online via live audio webcast on June 18, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 102,030,415 shares of common stock, or approximately 97% of the total outstanding shares eligible to be voted. The final voting results with respect to each proposal presented at the Annual Meeting are as follows:
Proposal One - Election of Directors
The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. The results of such vote were:
Votes ForVotes WithheldBroker Non-Votes
Caren Deardorf73,454,07623,532,3285,044,011
Weston Nichols, Ph.D.90,208,5646,777,8405,044,011
Stephanie S. Okey, M.S.72,225,31324,761,0915,044,011
Proposal Two - Ratification of Selection of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were:
Votes ForVotes AgainstAbstentions
101,675,974341,72712,714
Proposal Three - Approval, on an advisory basis, of the compensation of the Company’s named executive officers
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were:
Votes ForVotes AgainstAbstentionsBroker Non-Votes
91,657,9922,698,5382,629,8745,044,011


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Crinetics Pharmaceuticals, Inc.
Date:
June 22, 2026
By:/s/ R. Scott Struthers, Ph.D.
R. Scott Struthers, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)

Source: View Original Filing on SEC EDGAR

FAQ

What did Crinetics Pharmaceuticals (CRNX) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing three Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and approving on an advisory basis the compensation of named executive officers, with all three proposals receiving stockholder approval.

How many Crinetics Pharmaceuticals (CRNX) shares were represented at the 2026 annual meeting?

A total of 102,030,415 shares of common stock were represented virtually or by proxy at the annual meeting, equal to approximately 97% of the outstanding shares eligible to vote, indicating very high participation by stockholders.

Were all director nominees elected at the Crinetics Pharmaceuticals (CRNX) 2026 annual meeting?

Yes. Stockholders elected Caren Deardorf, Weston Nichols, Ph.D., and Stephanie S. Okey, M.S. as Class II directors for three-year terms expiring at the 2029 annual meeting, with each nominee receiving more votes for than withheld.

Did Crinetics Pharmaceuticals (CRNX) stockholders ratify the company’s independent auditor for 2026?

Yes. Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 101,675,974 votes for, 341,727 votes against, and 12,714 abstentions recorded.

How did Crinetics Pharmaceuticals (CRNX) stockholders vote on executive compensation in 2026?

On an advisory basis, stockholders approved the compensation of the company’s named executive officers, with 91,657,992 votes for, 2,698,538 against, 2,629,874 abstentions, and 5,044,011 broker non-votes reported for this say-on-pay proposal.

Filing Exhibits & Attachments

3 documents

Other Documents